For research use only. Not for therapeutic Use.
Dihydroartemisinin（Cat No.:I004684）is a potent antimalarial drug derived from artemisinin, known for its rapid action against Plasmodium parasites responsible for malaria. It targets the parasite in its blood-stage by producing reactive oxygen species that damage critical cellular structures, leading to parasite death. Often used in artemisinin-based combination therapies (ACTs), dihydroartemisinin enhances treatment efficacy and helps prevent drug resistance. With a favorable safety profile and quick onset, it is effective in treating both uncomplicated and drug-resistant malaria, making it a vital component in global malaria control and treatment strategies.
| Catalog Number | I004684 |
| CAS Number | 71939-50-9 |
| Synonyms | (3R,5aS,6R,8aS,9R,10R,12R,12aR)-3,6,9-trimethyldecahydro-3H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-ol |
| Molecular Formula | C15H24O5 |
| Purity | ≥95% |
| Target | Antimalaria |
| Solubility | 10 mM in DMSO |
| Storage | 3 years -20℃ powder |
| IUPAC Name | (1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol |
| InChI | InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12+,13-,14-,15-/m1/s1 |
| InChIKey | BJDCWCLMFKKGEE-ISOSDAIHSA-N |
| SMILES | C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)O)C |
| Reference | </br>1:Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer. Zhang F, Ma Q, Xu Z, Liang H, Li H, Ye Y, Xiang S, Zhang Y, Jiang L, Hu Y, Wang Z, Wang X, Zhang Y, Gong W, Liu Y.J Exp Clin Cancer Res. 2017 May 15;36(1):68. doi: 10.1186/s13046-017-0531-3. PMID: 28506239 Free PMC Article</br>2:Dihydroartemisinin inhibits the viability of cervical cancer cells by upregulating caveolin 1 and mitochondrial carrier homolog 2: Involvement of p53 activation and NAD(P)H:quinone oxidoreductase 1 downregulation. Zhang T, Hu Y, Wang T, Cai P.Int J Mol Med. 2017 May 9. doi: 10.3892/ijmm.2017.2980. [Epub ahead of print] PMID: 28498397 </br>3:Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine Exert Inverse Selective Pressure on <i>Plasmodium Falciparum</i> Drug Sensitivity-Associated Haplotypes in Uganda. Taylor AR, Flegg JA, Holmes CC, Guérin PJ, Sibley CH, Conrad MD, Dorsey G, Rosenthal PJ.Open Forum Infect Dis. 2016 Oct 25;4(1):ofw229. doi: 10.1093/ofid/ofw229. eCollection 2017 Winter. PMID: 28480232 Free PMC Article</br>4:Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy. Kang XJ, Wang HY, Peng HG, Chen BF, Zhang WY, Wu AH, Xu Q, Huang YZ.Acta Pharmacol Sin. 2017 May 8. doi: 10.1038/aps.2017.10. [Epub ahead of print] PMID: 28479604 </br>5:Post-licensure safety evaluation of dihydroartemisinin piperaquine in the three major ecological zones across Ghana. Oduro AR, Owusu-Agyei S, Gyapong M, Osei I, Adjei A, Yawson A, Sobe E, Baiden R, Adjuik M, Binka F.PLoS One. 2017 Mar 30;12(3):e0174503. doi: 10.1371/journal.pone.0174503. eCollection 2017. PMID: 28358871 Free PMC Article</br>6:Intermittent Preventive Treatment with Dihydroartemisinin-piperaquine for the Prevention of Malaria among HIV-infected Pregnant Women. Natureeba P, Kakuru A, Muhindo M, Littmann E, Ochieng T, Ategeka J, Koss CA, Plenty A, Charlebois ED, Clark TD, Nzarubara B, Nakalembe M, Cohan D, Rizzuto G, Muehlenbachs A, Ruel T, Jagannathan P, Havlir DV, Kamya MR, Dorsey G.J Infect Dis. 2017 Feb 22. doi: 10.1093/infdis/jix110. [Epub ahead of print] PMID: 28329368 </br>7:Treatment Failure of Dihydroartemisinin/Piperaquine for Plasmodium falciparum Malaria, Vietnam. Phuc BQ, Rasmussen C, Duong TT, Dong LT, Loi MA, Ménard D, Tarning J, Bustos D, Ringwald P, Galappaththy GL, Thieu NQ.Emerg Infect Dis. 2017 Apr;23(4):715-717. doi: 10.3201/eid2304.161872. PMID: 28322709 Free PMC Article</br>8:Dihydroartemisinin Sensitizes Human Lung Adenocarcinoma A549 Cells to Arsenic Trioxide via Apoptosis. Chen H, Gu S, Dai H, Li X, Zhang Z.Biol Trace Elem Res. 2017 Mar 6. doi: 10.1007/s12011-017-0975-5. [Epub ahead of print] PMID: 28261759 </br>9:Characterization of the selective alkylation site in hemoglobin A by dihydroartemisinin with tandem mass spectrometry. Tiensomjitr K, Prabpai S, Kongsaeree P.Int J Biol Macromol. 2017 Jun;99:358-364. doi: 10.1016/j.ijbiomac.2017.02.094. Epub 2017 Mar 1. PMID: 28259625 </br>10:Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine. Permala J, Tarning J, Nosten F, White NJ, Karlsson MO, Bergstrand M.Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02491-16. doi: 10.1128/AAC.02491-16. Print 2017 May. PMID: 28242661 Free PMC Article |
